Join/ Subscribe

Subscribe

We recognize the significance of content in the modern digital world. Sign up on our website to receive the most recent technology trends directly in your email inbox..


Safe and Secure

Free Articles

Join / Subscribe Us

Subscribe

We recognize the significance of content in the modern digital world. Sign up on our website to receive the most recent technology trends directly in your email inbox.





    We assure a spam-free experience. You can update your email preference or unsubscribe at any time and we'll never share your information without your consent. Click here for Privacy Policy.


    Safe and Secure

    Free Articles

    Samsung Biologics Reports Fourth Quarter & Fiscal Year 2023 Financial Results

    • Recorded Q4'23 consolidated revenue of KRW 1.07 trillion and Q4'23 operating profit of KRW 350 billion
    • Recorded FY'23 consolidated revenue of KRW 3.69 trillion and FY'23 operating profit of KRW 1.1 trillion
    • Exceeded KRW 1 trillion consolidated operating income for the first time, underscoring over a decade of operational excellence

    INCHEON, South Korea, Jan. 24, 2024 -- Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), announced robust financial results for the fourth quarter and fiscal year 2023.

    "We have achieved another remarkable milestone with our consolidated operating profit surpassing KRW 1 trillion in the 12 years since our founding in 2011. Our unwavering commitment to customer-centric services and continuous innovation remains at the core of our mission, ensuring the delivery of high-quality biomedicines to patients worldwide," said John Rim, CEO and President of Samsung Biologics. "Despite the challenging environment, we remain optimistic, anticipating continued growth driven by sustained partnerships, expanded capacity, and strategic portfolio diversification in the coming year."

    FOURTH QUARTER & FISCAL YEAR 2023 RESULTS

    In the fourth quarter of 2023, consolidated revenue recorded KRW 1.07 trillion, marking an 11.2% growth from KRW 965.5 billion in the same period from the previous year. This exceptional performance is attributed to the successful ramp-up of Plant 4 operation and a robust sales backlog. In 2023, Samsung Biologics accumulated contracts worth over USD 12 billion by expanding its partnerships with 14 of the top 20 global pharmaceutical companies.

    For the full-year 2023, the company posted a record-high consolidated operating profit of KRW 1.11 trillion, up by 13.2% from KRW 983.6 billion in 2022. Consolidated revenue reached KRW 3.69 trillion, reflecting a 23.1% increase from the previous year. The outlook remains strong, with resilient business performance expected to drive a 10-15% annual growth in revenue for 2024.

    [Consolidated Earnings, KRW billion]

    Q4'23

    Q4'22

    YoY change

    FY23

    FY22

    YoY change

    Revenues

    1,073.5

    965.5

    +108.0

    (+11.2%)

    3,694.6

    3,001.3

    +693.3

    (+23.1%)

    Operating Profit

    350.0

    312.8

    37.2

    (+11.9%)

    1,113.7

    983.6

    +130.1

    (+13.2%)

    EBITDA

    491.9

    405.2

    +86.7

    (+21.4%)

    1,603.5

    1,291.9

    311.6

    (+24.1%)

    On a standalone basis, Samsung Biologics recorded a revenue of KRW 2.94 trillion and operating profit of KRW 1.2 trillion in 2023. In the fourth quarter of 2023 alone, the company posted a revenue of KRW 827.9 billion and operating profit of KRW 334.0 billion.

    FISCAL YEAR 2024 OUTLOOK

    Building on this momentum, Samsung Biologics plans to continue making strategic investments in expanding capacity and global reach, while enhancing capabilities to better meet clients' evolving needs.

    With Plant 4's full operation, commenced in 2023 as previously committed, the increased production capacity is expected to gradually enhance its contribution to future revenue. Having successfully completed engineering run and Process Performance Qualification (PPQ), and obtained regulatory approval for large-scale production, Plant 4 is projected to contribute approximately 30% of drug substance manufacturing business revenue by 2025. Plant 5, the first facility of the company's second Bio Campus, is set to begin operations in April 2025, five months ahead of its initial construction timeline.

    To accommodate each client's ever-evolving needs, Samsung Biologics introduced customized CMC solutions: three development packages designed to ensure maximum flexibility and meet clients' goals per their development stage. The company's newly launched development platforms, S-CHOsient™ and S-Glyn™, will also help ensure successful development with higher productivity and quality.

    In an effort to diversify its business portfolio, the company's separate antibody-drug conjugate (ADC) manufacturing facility is set to be cGMP-ready within 2024, enabling the exploration of innovative technologies for next-generation biomedicines. This aligns with investments the company has made through the Samsung Life Science Fund, supporting pioneering biotechs like AimedBio and Araris Biotech AG in ADC technology.

    Samsung Biologics also continues to engage and drive action in the sustainability front. As a member of the Sustainable Markets Initiative's Health Systems Task Force, Samsung Biologics, along with 13 other global public-private health system leaders, has committed to bringing practical solutions to decarbonizing healthcare supply chains. The company will further strengthen partnerships with suppliers to foster collaboration, while continuing to establish a concrete roadmap for ESG management. Recently, Samsung Biologics was awarded the EcoVadis' Platinum Sustainability Rating, the highest recognition given, for the company's sustainable management practices.

    For more details on performance and financials, please refer to the Earnings Release.

    About Samsung Biologics Co., Ltd.

    Samsung Biologics (KRX: 207940.KS) is a fully integrated, end-to-end CDMO service provider, offering seamless development and manufacturing solutions from cell line development to final aseptic fill/finish as well as laboratory testing support for the biopharmaceutical products we manufacture. Our state-of-the-art facilities are cGMP compliant with bioreactors ranging from small to large scales to serve varying client needs. To maximize our operational efficiency and expand our capabilities in response to growing biomanufacturing demand, Samsung Biologics recently completed Bio Campus I with Plant 4 offering a combined 604KL total capacity, and launched Bio Campus II with the construction of Plant 5, which will be operational in April 2025 adding 180KL biomanufacturing capacity. Additionally, Samsung Biologics America enables the company to work in closer proximity to clients based in the U.S. and Europe. We continue to upgrade our capabilities to accommodate our clients by investing in technologies such as an antibody-drug conjugate (ADC) facility, a dedicated mRNA manufacturing facility, and additional aseptic filling capacity. As a sustainable CDMO partner of choice, we are committed to on-time, in-full delivery of the products we manufacture with our flexible manufacturing solutions, operational excellence, and proven expertise.

    View original content:https://www.prnewswire.com/news-releases/samsung-biologics-reports-fourth-quarter--fiscal-year-2023-financial-results-302042891.html

    SOURCE Samsung Biologics

    Tags :

    Scroll to Top